New drug combo before surgery for stomach cancer
Treatments studied
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach cancer or gastroesophageal junction cancer that is locally advanced (has spread to nearby tissue or lymph nodes) but can still be removed with surgery.
- You have not had prior chemotherapy, radiation, or other cancer treatments.
- Your cancer is HER2-negative (a type of cancer that doesn't have a specific protein).
- You are generally well enough to be active (able to do light activity, like walking) and have adequate organ function.
- You are not pregnant or breastfeeding, and if you can have children, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (immunotherapy plus a targeted pill plus chemo) versus a standard combo (immunotherapy plus chemo) before surgery, for people with stage IV stomach cancer. The goal is to see if this approach can shrink the cancer enough to make it removable, potentially improving outcomes.
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two immunotherapy drugs, bevacizumab, and chemotherapy given before surgery for advanced ovarian cancer. The goal is to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (albumin-bound paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.